Paenidigyamycin g: 1-acetyl-2,4-dimethyl-3-phenethyl-1H-imidazol-3-ium
Özet
The Ghanaian Paenibacillus sp. DE2SH (GenBank Accession Number: MH091697) is a prolific producer of potent antiparasitic alkaloids. Further detailed study of the culture broth of this strain produced the compound Paenidigyamycin G (1), which is a derivative of the known antiparasitic compound Paenidigyamycin A (2). Compound (1) was isolated on HPLC at tR ≈ 37.5 min and its structure determined by IR, UV, MS, 1D, and 2D-NMR data. Compound 1 produced weak to moderate antileishmanial and antitrypanosomal activity when tested against Leishmania donovani (Laveran and Mesnil) Ross (D10) and Trypanosoma brucei subsp. brucei strain GUTat 3.1 with IC50 = 115.41 and 28.75 µM, respectively. This result is interesting since the parent compound 2 is known to possess consistent and potent antiparasitic activity. However, 1 displayed a promising selectivity profile towards T. brucei subsp. brucei due to its relatively low toxicity against normal mouse macrophages RAW 264.7 cells (SI = 8.70). Given that compound 1 is also the main metabolite found in the hexane fraction of all extracts produced by Paenibacillus sp. DE2SH when it is co-cultured with other bacteria strains, it must possess some unique biological functions which should make it an excellent candidate for further biological activity screening in other bioassays.
Anahtar Kelimeler
- Scopus
- 4
- WoS
- 3
- OpenAlex
- 4
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Tetevi, Gilbert Mawuli | |
| dc.contributor.author | Kwain, Samuel | |
| dc.contributor.author | Mensah, Thomas | |
| dc.contributor.author | Camas, Anil Sazak | |
| dc.contributor.author | Camas, Mustafa | |
| dc.contributor.author | Dofuor, Aboagye Kwarteng | |
| dc.contributor.author | Azerigyik, Faustus Akankperiwen | |
| dc.contributor.author | Oluwabusola, Emmanuel | |
| dc.contributor.author | Deng, Hai | |
| dc.contributor.author | Jaspars, Marcel | |
| dc.contributor.author | Kyeremeh, Kwaku | |
| dc.date.accessioned | 2026-10-28T14:56:47.672573492Z | |
| dc.date.available | 2026-10-28T14:56:47.672573492Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | The Ghanaian Paenibacillus sp. DE2SH (GenBank Accession Number: MH091697) is a prolific producer of potent antiparasitic alkaloids. Further detailed study of the culture broth of this strain produced the compound Paenidigyamycin G (1), which is a derivative of the known antiparasitic compound Paenidigyamycin A (2). Compound (1) was isolated on HPLC at tR ≈ 37.5 min and its structure determined by IR, UV, MS, 1D, and 2D-NMR data. Compound 1 produced weak to moderate antileishmanial and antitrypanosomal activity when tested against Leishmania donovani (Laveran and Mesnil) Ross (D10) and Trypanosoma brucei subsp. brucei strain GUTat 3.1 with IC50 = 115.41 and 28.75 µM, respectively. This result is interesting since the parent compound 2 is known to possess consistent and potent antiparasitic activity. However, 1 displayed a promising selectivity profile towards T. brucei subsp. brucei due to its relatively low toxicity against normal mouse macrophages RAW 264.7 cells (SI = 8.70). Given that compound 1 is also the main metabolite found in the hexane fraction of all extracts produced by Paenibacillus sp. DE2SH when it is co-cultured with other bacteria strains, it must possess some unique biological functions which should make it an excellent candidate for further biological activity screening in other bioassays. | |
| dc.description.sponsorship | Cambridge-Africa Partnership for Research Excellence | |
| dc.description.sponsorship | Mauritius Research Council, MRC | |
| dc.description.sponsorship | Carnegie | |
| dc.description.sponsorship | MSD K.K. | |
| dc.description.sponsorship | University of Ghana, UG | |
| dc.description.sponsorship | Department for International Development, UK Government, DFID | |
| dc.description.sponsorship | Department for International Development, DFID | |
| dc.description.sponsorship | Carnegie Corporation of New York, CCNY | |
| dc.description.sponsorship | MRC/DFID | |
| dc.description.sponsorship | African Research Leaders Award | |
| dc.description.sponsorship | Research Councils UK, RCUK | |
| dc.description.sponsorship | The Academy of Sciences for the Developing World, TWAS, (Award_17-512 RG/CHE/AF/AC_G) | |
| dc.description.sponsorship | The Academy of Sciences for the Developing World, TWAS | |
| dc.description.sponsorship | UK Research and Innovation, UKRI, (MR/S00520X/1) | |
| dc.description.sponsorship | UK Research and Innovation, UKRI | |
| dc.identifier.articlenumber | M1094 | |
| dc.identifier.doi | 10.3390/m1094 | |
| dc.identifier.eissn | 1422-8599 | |
| dc.identifier.issn | 1422-8599 | |
| dc.identifier.issue | 4 | |
| dc.identifier.scopus | 2-s2.0-85075528182 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/munzur/3559 | |
| dc.identifier.volume | 2019 | |
| dc.identifier.wos | WOS:000505584600006 | |
| dc.language.iso | en | |
| dc.publisher | MDPI AG | |
| dc.relation.ispartof | MolBank | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Alkaloid | |
| dc.subject | Antileishmanials | |
| dc.subject | Antitrypanosomals | |
| dc.subject | Imidazole | |
| dc.subject | Leishmaniasis | |
| dc.subject | Paenibacillus | |
| dc.subject | Trypanosomiasis | |
| dc.subject.classification | Chemistry, Organic | |
| dc.subject.classification | Chemistry | |
| dc.subject.other | IMIDAZOLE DERIVATIVES | |
| dc.title | Paenidigyamycin g: 1-acetyl-2,4-dimethyl-3-phenethyl-1H-imidazol-3-ium | |
| dc.type | Article | |
| rdl.citation.openalex | 4 | |
| rdl.citation.scopus | 4 | |
| rdl.citation.wos | 3 | |
| rdl.oa.status | gold | |
| rdl.oa.url | https://www.mdpi.com/1422-8599/2019/4/M1094/pdf?version=1574354709 | |
| rdl.scopus.quartile | Q4 | |
| rdl.sdg | SDG03 | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.wos.index | Emerging Sources Citation Index (ESCI) |

